Optimizing Therapy in the Diabetic Patient with Renal Disease: Antihypertensive Treatment

Journal of the American Society of Nephrology

Volumn 15, Issue 1 SUPPL., 2004, Pages

  Deferrari, Giacomo ^a,b   Ravera, Maura ^a   Berruti, Valeria ^a   Leoncini, Giovanna ^a   Deferrari, Luca ^a  

^a UNIVERSITY OF GENOA   (Italy)

^b Department of Internal Medicine ^*  (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALDOSTERONE; ANGIOTENSIN; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; CALCIUM CHANNEL BLOCKING AGENT; CREATININE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; IRBESARTAN; RENIN; TRANSFORMING GROWTH FACTOR BETA;

ANTIHYPERTENSIVE THERAPY; CARDIOVASCULAR RISK; CLINICAL TRIAL; COMORBIDITY; CONFERENCE PAPER; DIABETES MELLITUS; DRUG INDICATION; HEART PROTECTION; HUMAN; HYPERTENSION; KIDNEY DISEASE; MICROALBUMINURIA; OUTCOMES RESEARCH; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; RISK MANAGEMENT;

EID: 0346881275     PISSN: 10466673     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (55)

1. Parving HH, Osterby R, Ritz E: Diabetic nephropathy. In: The Kidney, edited by Brenner BM, Philadelphia, WB Saunders, 2000, pp 1731-1773
2. Kaplan NM: Management of hypertension in patients with type 2 diabetes mellitus. Guidelines based on current evidence. Ann Intern Med 135: 1079-1183, 2001
3. Lindoholm LH, Ibsen H, Dahlof B, Devereux RB, Beevers G, de Faire U, Fyhrquist F, Julius S, Kjeldsen SE, Kristiansson K, Lederballe-Pedersen O, Nieminen MS, Omvik P, Oparil S, Wedel H, Aurup P, Edelman J, Snapinn S, The LIFE Study Group: Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint Reduction in Hypertension study (LIFE): A randomized trial against atenolol. Lancet 359: 1004-1010, 2002
4. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 289: 2560-2572, 2003
5. Guidelines Committee. 2003 European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens 21: 1011-1053, 2003
6. American Diabetes Association: Treatment of Hypertension in adults with diabetes. Diabetes Care 25: 199-201, 2002
7. Deferrari G, Cavallo Perin P, Di Paolo S, Locateli R, Nosadini R, Penno G, Piccoli G, Ravera M: Linee guida della nefropatia diabetica. Giornale Italiano Nefrologia 2002, in press
8. Miettinen H, Haffner SM, Lehto S, Ronnemaa T, Pyorala K, Laakso M: Proteinuria predicts stroke and other atherosclerotic vascular disease events in non diabetic and non-insulin-dependent diabetic subjects. Stroke 27: 2033-2039, 1996
9. Hollenberg NK: Non insulin dependent diabetes mellitus nephropathy and the renin system. J Hypertens Suppl 15: S7-S13, 1997
10. Schwartz MM, Lewis EJ, Leonard-Martin T, Lewis JB, Battle D: Renal pathology patterns in type 2 diabetes mellitus: relation with retinopathy. The Collaborative Study Group. Nephrol Dial Transplant 13: 2547-2552, 1998
11. Rodby R, Gilbert R, for the Collaborative Study Group: The presence of retinopathy is associated with poor renal and cardiovascular outcomes in type 2 diabetic nephropathy [Abstract]. J Am Soc Nephrol 13: A854, 2002
12. Ravid M, Brosh D, Ravid-Safran D, Levy Z, Rachmany R: Main risk factors for nephropathy in type 2 diabetes mellitus are plasma cholesterol levels, mean blood pressure and hyperglycemia. Arch Intern Med 158: 998-1004, 1998
13. Mathiesen ER, Hommel E, Hansen HP, Smidt UM, Parving HH: Randomised controlled trial of long term efficacy of captopril on preservation of kidney function in normotensive patients with insulin dependent diabetes and microalbuminuria. Br Med J 319: 24-25, 1999
14. Crepaldi G, Carta Q, Deferrari G, Mangili R, Navalesi R, Santeusanio F, Spalluto A, Vanasia A, Villa GM, Nosadini R, The Italian Microalbuminuria Study Group in IDDM: Effects of lisinopril and nifedipine on the progression to overt albuminuria in IDDM patients with incipient nephropathy and normal blood pressure. Diabetes Care 21: 104-110, 1998
15. Penno G, Chaturvedi N, Talmud PJ, Cotroneo P, Manto A, Nannipieri M, Luong L, Fuller J, The Euclid Study Group: Effect of angiotensin-converting enzyme (ACE) gene polymorphism on progression of renal disease and the influence of ACE inhibition in IDDM patients. Findings from the Euclid randomized controlled trials. Diabetes 47: 1507-1511, 1998
16. Ravid M, Savin H, Jutrin I, Bental T, Katz B, Lishner M: Long-term stabilizing effect of angiotensin-converting enzyme inhibition on plasma creatinine and on proteinuria in normotensive type II diabetic patients. Ann Intern Med 118: 577-581, 1993
17. Heart Outcomes Prevention Evaluation Study Investigators: Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: Results of the HOPE study and MICRO-HOPE sub-study. Heart Outcomes Prevention Evaluation Study Investigators. Lancet 355: 253-259, 2000
18. Lebovitz HE, Wiegmann TB, Cnaan A, Shahinfar S, Sica DA, Broadstone V, Scwartz SL, Mengel MC, Segal R, Versaggi JA: Renal protective effects of enalapril in hypertensive NIDDM: Role of baseline albuminuria. Kidney Int Suppl 45: S150-S155, 1994
19. Chan JC, Ko GT, Leung DH, Cheung RC, Cheung MY, So WY, Swaminathan R, Nicholls MG, Critcheley JA, Cockram C: Long term effects of angiotensin-converting enzyme inhibition and metabolic control in hypertensive type two diabetic patients. Kidney Int 57: 590-600, 2000
20. Estacio RO, Jeffers BW, Gifford N, Shrier N: Effect of blood pressure control on diabetic microvascular complications in patients with hypertension and type 2 diabetes. Diabetes Care 23[Suppl 2]: B54-B64, 2000.
21. Baba S, The J-mind Study Group: Nifedipine and enalapril equally reduce the progression of nephropathy in hypertensive type 2 diabetics. Diab Res 54: 191-201, 2001
22. Parving HH, Lehenert H, Brochner-Mortensen J, Gomis R, Andersen S, Arner P: Irbesartan in patients with type 2 Diabetes and Microalbuminuria Study Group: The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 345: 870-878, 2001
23. Deferrari G, Ravera M, Berruti V: Treatment of diabetic nephropathy in its early stages. Diabetes Metab Res Rev 19: 101-114, 2003
24. Pohl MA, Blumenthal S, Hunsicker LG, the Collaborative Study Group: Impact of achieved systolic blood pressure on renal function in type 2 diabetic nephropathy [Abstract]. J Am Soc Nephrol 13: A853, 2002
25. Bjork S, Mulec H, Johnsen SA, Norden G, Aurell M: Renal protective effect of enalapril in diabetic nephropathy. Br Med J 304: 339-343, 1992
26. Elving LD, Wetsel JF, Van Lier HJ, De Nobel E, Berden JH: Captopril and atenolol are equally effective in retarding the progression of diabetic nephropathy. Diabetologia 37: 604-609, 1994
27. Lewis EJ, Hunsicker LG, Bain RP, Rohode RD: The effect of angiotensin converting enzyme inhibition on diabetic nephropathy. N Engl J Med 329: 1456-1462, 1993
28. Tarnow L, Rossing P, Jensen C, Hansen BV, Parving HH: Long-term renoprotective effect of nisoldipine and lisinopril in type 1 diabetic patients with diabetic nephropathy. Diabetes Care 23: 1725-1730, 2000
29. Hovind P, Rossing P, Tarnow L, Smidt UM, Parving HH: Progression of diabetic nephropathy. Kidney Int 59: 702-709, 2001
30. Lebovitz HE, Wiegmann TB, Cnaan A, Shahinfar S, Sica DA, Broadstone V, Schwartz SL, Mengel MC, Segal R, Versaggi JA, Bolton WK: Renal protective effects of enalapril in hypertensive NIDDM: Role of baseline albuminuria. Kidney Int 45[suppl 45]: 150-155, 1994
31. Bakris GL, Copley JB, Vicknair N, Sadler R, Leurgans S: Calcium channel blockers versus other antihypertensive therapies on progression of NIDDM associated nephropathy. Kidney Int 50: 1641-1650, 1996
32. Nielsen FS, Rossing P, Gall MA, Skott P, Smidt UM, Parving HH: Long-term effect of lisinopril and atenolol on kidney function in hypertensive NIDDM subjects with diabetic nephropathy. Diabetes 46: 1182-1188, 1997
33. Fogari R, Zoppi A, Corradi L, Mugellini A, Lazzari P, Preti P, Lusardi P: Long-term effects of ramipril and nitrendipine on albuminuria in hypertensive patients with type 2 diabetes and impaired renal function. J Hum Hypertens 13: 47-53, 1999
34. Lewis EJ, Hunsicker LG, Clarke WR, Berl T, Pohl MA, Lewis JB, Ritz E, Atkins RC, Rohode R, Raz I, Collaborative Study Group: Renoprotective effect of the angiotensin receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 345: 851-860, 2001
35. Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving HH, Remuzzi G, Snappin SM, Zhang Z, Shahinfar S, RENAAL Study Investigators: Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 345: 861-869, 2001
36. Atkins RC, Briganti EM, Wiegmann TB, on behalf of the Collaborative Study Group: Effect of baseline proteinuria and change in proteinuria with treatment on the risk of renal end-points in the Irbesartan Diabetic Nephropathy Trial (IDNT) [Abstract]. J Am Soc Nephrol 13: A33, 2002
37. Rossing K, Christensen PK, Jensen BR, Parving HH: Dual blockade of the renin-angiotensin system in diabetic nephropathy: a randomized double-blind crossover study. Diabetes Care 25: 95-100, 2002
38. Laverman GD, Navis G, Henning RH, de Jong PE, de Zeeuw D: Dual renin-angiotensin system blockade at optimal doses for proteinuria. Kidney Int 62: 1020-1025, 2002
39. Nakao N, Yoshimura A, Morita H, Takada M, Kayano T, Ideura T: Combination treatment of angiotensin-II receptor blocker and angiotensin-converting-enzyme inhibitor in non-diabetic renal disease (COOPERATE): A randomised controlled trial. Lancet 361: 117-124, 2003
40. Sato A, Hayashi K, Naruse M, Satura T: Effectiveness of aldosterone blockade in patients with diabetic nephropathy. Hypertension 41: 64-68, 2003
41. UK Prospective Diabetes Study Group: Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. Br Med J 317: 703-713, 1998
42. Schrier RW, Estacio RO, Esler A, Meheler P: Effects of aggressive blood pressure control in normotensive type 2 diabetic patients on albuminuria, retinopathy and strokes. Kidney Int 61: 1086-1097, 2002
43. Curb JD, Pressel SL, Cutler JA, Savage PJ, Applegate WB, Black H, Camel G, Davis BR, Frost PH, Gonzalez N, Guthrie G, Oberman A, Rutan GH, Stamler J: Effect of diuretic-based antihypertensive treatment on cardiovascular disease risk in older diabetic patients with isolated systolic hypertension. Systolic Hypertension in the Elderly Program Cooperative Research Group. JAMA 276: 1886-1892, 1996
44. Tuomilehto J, Rastenyte D, Birkenhager WH, Thijs L, Antikainen R, Bulpitt CJ, Fletcher AE, Forette F, Goldhaber A, Palatini P, Sarti C, Fagard R: Effects of calcium-channel blockade in older patients with diabetes and systolic hypertension. Systolic Hypertension in Europe Trial Investigators. N Engl J Med 340: 677-684, 1999
45. Hansson L, Zanchetti A, Carruthers SG, Dahlof B, Elmfeldt D, Julius S, Menard J, Rahn KH, Wedel H, Westerling S: Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. Lancet 351: 1755-1762, 1998
46. Estacio RO, Schrier RW: Antihypertensive therapy in type 2 diabetes: Implications of the appropriate blood pressure control in diabetes (ABCD) trial. Am J Cardiol 82: 9R-14R, 1998
47. Hansson L: Recent intervention trials in hypertension initiated in Sweden-HOT, CAPPP and others. Hypertension Optimal Treatment Study. Captopril Prevention Project. Clin Exp Hypertens 21: 507-515, 1999
48. Niskanen L, Hedner T, Hansson L, Lanke J, Niklason A, CAPPP Study Group: Reduced cardiovascular morbidity and mortality in hypertensive diabetic patients on first-line therapy with an ACE inhibitor compared with a diuretic/beta-blocker-based treatment regimen: A subanalysis of the Captopril Prevention Project. Diabetes Care 24: 2091-2096, 2001
49. Tatti P, Pahor M, Byington RP, Di Mauro P, Guarisco R, Strollo G, Strollo F: Outcome results of the Fosinopril Versus Amlodipine Cardiovascular Events Randomized Trial (FACET) in patients with hypertension and NIDDM. Diabetes Care 21: 597-603, 1998
50. UK Prospective Diabetes Study Group: Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39. Br Med J 317: 713-726, 1998
51. Lindholm LH, Hansson L, Ekbom T, Dahlof B, Lanke J, Linjer E, Schersten B, Wester PO, Hedner T, de Faire U: Comparison of antihypertensive treatments in preventing cardiovascular events in elderly diabetic patients: results from the Swedish Trial in Old Patients with Hypertension-2. STOP Hypertension-2 Study Group. J Hypertens 18: 1671-1675, 2000
52. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial: Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 288: 2981-2997, 2002
53. Hansson L, Hedner T, Lund-Johansen P, Kjeldsen SE, Lindholm LH, Syvertsen JO, Lanke J, de Faire U, Dahlof B, Karlberg BE: Randomised trial of effects of calcium antagonists compared with diuretics and beta-blockers on cardiovascular morbidity and mortality in hypertension: the Nordic Diltiazem (NORDIL) study. Lancet 356: 359-65, 2000
54. Brown MJ, Palmer CR, Castaigne A, de Leeuw PW, Mancia G, Rosenthal T, Ruilope LM: Morbidity and mortality in patients randomised to double-blind treatment with a long-acting calcium-channel blocker or diuretic in the International Nifedipine GITS study: Intervention as a Goal in Hypertension Treatment (INSIGHT). Lancet 356: 366-72, 2000
55. Gaede P, Vedel P, Larsen N, Jensen GV, Parving HH, Pedersen O: Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med 348: 383-93, 2003